Study S001648

Examining the Utility of GLP-1 Agonists as Neuroprotective Agents Through a Pilot Clinical Trial in High Risk Population With Neurocognitive Deficits and Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06171152
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: EARLY_PHASE1
Masking: NONE
Status: SUSPENDED
Enrollment: 30
Start: 2024-01-26
Primary completion: 2027-06-01
Lead sponsor: University of Chicago
Conditions: Multiple Sclerosis; Long COVID; Long Covid19; Obese; Obesity; Obesity, Morbid; Acute Leukemia in Remission
Interventions: DRUG:Liraglutide Pen Injector [Saxenda]; OTHER:Medication Diary
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Change from Baseline in Serum Brain Derived Neurotrophic Factor (BDNF) after 8 Weeks [8 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.